These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 20952196)

  • 1. Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
    Lee J; Kim JY; Choi J; Lee SH; Kim J; Lee J
    Bioorg Med Chem Lett; 2010 Dec; 20(23):7046-9. PubMed ID: 20952196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel macrocyclic C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Kim MJ; Lee SH; Park SO; Kang H; Lee JS; Lee KN; Jung ME; Kim J; Lee J
    Bioorg Med Chem; 2011 Sep; 19(18):5468-79. PubMed ID: 21868239
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.
    Park EJ; Kong Y; Lee JS; Lee SH; Lee J
    Bioorg Med Chem Lett; 2011 Jan; 21(2):742-6. PubMed ID: 21193308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Feng Y; Lv B; Xu G; Zhang L; Du J; Peng K; Xu M; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem; 2010 Jun; 18(12):4422-32. PubMed ID: 20576578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: 1,3,4-Thiadiazolylmethylphenyl glucoside congeners.
    Lee J; Lee SH; Seo HJ; Son EJ; Lee SH; Jung ME; Lee M; Han HK; Kim J; Kang J; Lee J
    Bioorg Med Chem; 2010 Mar; 18(6):2178-2194. PubMed ID: 20181486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1.
    Zhang X; Urbanski M; Patel M; Zeck RE; Cox GG; Bian H; Conway BR; Pat Beavers M; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2005 Dec; 15(23):5202-6. PubMed ID: 16198559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
    Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
    Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
    Ding Y; Mao L; Xu D; Xie H; Yang L; Xu H; Geng W; Gao Y; Xia C; Zhang X; Meng Q; Wu D; Zhao J; Hu W
    Bioorg Med Chem Lett; 2015 Jul; 25(14):2744-8. PubMed ID: 26026363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
    Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Xu B; Feng Y; Cheng H; Song Y; Lv B; Wu Y; Wang C; Li S; Xu M; Du J; Peng K; Dong J; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Roberge JY; Seed B; Chen Y
    Bioorg Med Chem Lett; 2011 Aug; 21(15):4465-70. PubMed ID: 21737266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
    J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners.
    Kim MJ; Lee J; Kang SY; Lee SH; Son EJ; Jung ME; Lee SH; Song KS; Lee M; Han HK; Kim J; Lee J
    Bioorg Med Chem Lett; 2010 Jun; 20(11):3420-5. PubMed ID: 20434909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.
    Lee SH; Kim MJ; Lee SH; Kim J; Park HJ; Lee J
    Eur J Med Chem; 2011 Jul; 46(7):2662-75. PubMed ID: 21514014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CoMFA and CoMSIA studies on C-aryl glucoside SGLT2 inhibitors as potential anti-diabetic agents.
    Vyas VK; Bhatt HG; Patel PK; Jalu J; Chintha C; Gupta N; Ghate M
    SAR QSAR Environ Res; 2013; 24(7):519-51. PubMed ID: 23305412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
    Pan X; Huan Y; Shen Z; Liu Z
    Eur J Med Chem; 2016 May; 114():89-100. PubMed ID: 26974378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel thiophenyl C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents.
    Lee SH; Song KS; Kim JY; Kang M; Lee JS; Cho SH; Park HJ; Kim J; Lee J
    Bioorg Med Chem; 2011 Oct; 19(19):5813-32. PubMed ID: 21906953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and biological evaluation of novel dioxa-bicycle C-aryl glucosides as SGLT2 inhibitors.
    Yan Q; Ding N; Li Y
    Carbohydr Res; 2016 Feb; 421():1-8. PubMed ID: 26735747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.
    Yamamoto Y; Kawanishi E; Koga Y; Sakamaki S; Sakamoto T; Ueta K; Matsushita Y; Kuriyama C; Tsuda-Tsukimoto M; Nomura S
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5641-5. PubMed ID: 23999047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Xu B; Feng Y; Peng K; Xu G; Du J; Zhang L; Zhang W; Zhang T; Zhu L; Ding H; Sheng Z; Welihinda A; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Dec; 19(24):6877-81. PubMed ID: 19896374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.